Researchers announced promising early results from a clinical trial of a new oral medication, RGT-61159, aimed at treating advanced adenoid cystic carcinoma (ACC) and colorectal cancer (CRC). In patients receiving the recommended dose, the drug achieved an impressive 84.6% disease control rate, with some patients showing partial responses to treatment. This suggests that RGT-61159 could be an effective option for people facing these aggressive cancers, providing hope for better management of their conditions.

For those concerned about cancer and its impact on longevity, these findings are particularly significant. The trial included patients with advanced forms of ACC and CRC, both of which have limited treatment options and high unmet medical needs. The drug not only demonstrated a high disease control rate but also showed a favorable safety profile, meaning it was well-tolerated by patients. Common side effects were manageable, including fatigue and nausea, which is encouraging for anyone looking for effective cancer treatments that don’t come with debilitating side effects.

The research is still in its early stages, as this is a Phase 1a/b clinical trial. While the results are promising, more data is needed to confirm the drug’s effectiveness and safety over the long term. The ongoing study aims to gather further evidence on how well RGT-61159 works and its potential as a treatment for other cancers driven by the MYB oncogene.

If you or someone you know is facing cancer, staying informed about new treatments like RGT-61159 is crucial. While this drug is not yet widely available, it highlights the importance of ongoing research in finding effective therapies for difficult-to-treat cancers. Always consult with a healthcare professional about the latest options and what might be best for individual health needs.

Source: globenewswire.com